Literature DB >> 10731632

Alteration of the glucocorticoid receptor subcellular localization by non steroidal compounds.

V Prima1, C Depoix, B Masselot, P Formstecher, P Lefebvre.   

Abstract

The glucocorticoid receptor (GR) engages transient or stable interactions with chaperones (hsp90, hsp70), co-chaperones (p60/hop, hsp40) and several other polypeptides such as immunophilins (Cyp40, FKBP59) and p23 to achieve a high affinity ligand binding state. This complex dissociates in response to hormonal stimuli and holo-GR translocates into the nucleus, where it regulates the activity of glucocorticoid-sensitive genes. GR activity is controlled through its ligand binding domain by steroids displaying either agonistic or antagonistic activity. An alternative approach to modulate GR activity is to target receptor-associated proteins (RAPs), and several non steroidal compounds binding to RAPs affect GR transcriptional activity. We have studied the effect of such drugs on the intracellular localization of a EGFP-GR fusion protein, which has wild type GR pharmacological properties. Agonist and antagonist binding induced nuclear translocation of GR, whereas rifampicin was found to be inactive in our system. Immunosuppressants FK506 and cyclosporin A were able to induce partial nuclear translocation of GR, suggesting that potentiation of glucocorticoid action by these compounds may also proceed through enhanced GR nuclear transfer. Short treatment of cells with the hsp90 inhibitor geldanamycin (GA) did not prevent nuclear translocation of GR. However, longer treatments, in parrallel to the inhibition of GR transcriptional activity, strongly perturbed GR subcellular localization concomitantly to the disruption of the actin network, and caused GR aggregation and down-regulation. The GA-induced transcriptional shutdown was also observed for other nuclear receptors which do not interact stably with hsp90. Thus RAP-binding compounds may exert their effects at least in part through perturbation of the GR cytosol to nucleus partitioning, and identify these proteins as valuable therapeutic targets to control nuclear receptor activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731632     DOI: 10.1016/s0960-0760(99)00146-6

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

1.  Chlamydia pneumoniae activates epithelial cell proliferation via NF-kappaB and the glucocorticoid receptor.

Authors:  Mikael M Cornelsen Gencay; Michael Tamm; Allan Glanville; André P Perruchoud; Michael Roth
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

2.  Solubility-promoting function of Hsp90 contributes to client maturation and robust cell growth.

Authors:  Natalie W Pursell; Parul Mishra; Daniel N A Bolon
Journal:  Eukaryot Cell       Date:  2012-06-01

3.  Fluorescent protein-labeled glucocorticoid receptor alpha isoform trafficking in cultured human trabecular meshwork cells.

Authors:  Adnan Dibas; Ming Jiang; Rafal Fudala; Ignacy Gryczynski; Zygmunt Gryczynski; Abbot F Clark; Thomas Yorio
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

4.  Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.

Authors:  Chang-Kwon Oh; Su Jin Kim; Ji Hye Kim; Jong Hoon Lee
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

5.  Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain.

Authors:  L Fang; D Ricketson; L Getubig; B Darimont
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-27       Impact factor: 11.205

6.  A Quantitative Study of Internal and External Interactions of Homodimeric Glucocorticoid Receptor Using Fluorescence Cross-Correlation Spectroscopy in a Live Cell.

Authors:  Manisha Tiwari; Sho Oasa; Johtaro Yamamoto; Shintaro Mikuni; Masataka Kinjo
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.